Provided by Tiger Trade Technology Pte. Ltd.

CEL-SCI Corp

2.06
+0.270015.08%
Post-market: 2.100.0431+2.09%19:58 EDT
Volume:479.38K
Turnover:959.76K
Market Cap:36.23M
PE:-0.80
High:2.09
Open:1.80
Low:1.78
Close:1.79
52wk High:10.83
52wk Low:0.8900
Shares:17.59M
Float Shares:16.85M
Volume Ratio:5.15
T/O Rate:2.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.5688
EPS(LYR):-6.2655
ROE:-252.53%
ROA:-66.82%
PB:3.31
PE(LYR):-0.33

Loading ...

SCI Says Oral Oncology Accepts Multikine Phase 3 Data Showing Survival Benefit in Low PD-L1 Oral Cancer Patients

Reuters
·
Jul 30

First Berlin Reiterates Buy on Cel-sci, Cuts Price Target to USD 15

Reuters
·
Jul 20

Ecopetrol's Acquisition Appeal Backed by Brazilian Regulator, Reviving Takeover Process

Deep News
·
Jul 17

Press Release: Ecopetrol Reports CVM Decision on Appeal Related to the Tender Offer

Dow Jones
·
Jul 16

SCI Notifies Availability of Multikine Phase 3 Confirmatory Study Launch Release

Reuters
·
Jul 13

SCI Corp - to Launch Phase 3 Confirmatory Study for Multikine in Head and Neck Cancer

THOMSON REUTERS
·
Jul 13

SCI Corp - Patient Enrollment to Begin in U.S., Europe, Asia, and South America

THOMSON REUTERS
·
Jul 13

SCI Announces Annual Shareholder Meeting

Reuters
·
Jul 03

CEL-SCI, Saudi Amarox hold strategic agreement signing at BIO 2026

TIPRANKS
·
Jun 24

SCI Signs Agreement with Saudi Amarox to Support Multikine Commercialization in Saudi Arabia

Reuters
·
Jun 24

SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at Bio 2026, Advancing U.s.–saudi Cooperation in Cancer Care

THOMSON REUTERS
·
Jun 24

BRIEF-CEL-SCI Announces Closing Of Offering

Reuters
·
Jun 17

CEL-SCI Closes $2.5 Million Stock Offering

MT Newswires Live
·
Jun 17

CEL-SCI closes 2,500,000-share follow-on offering at USD 1 per share

Reuters
·
Jun 17

CEL-SCI Announces Closing of Offering

THOMSON REUTERS
·
Jun 17

CEL-SCI highlights dual-track strategy for Multikine

TIPRANKS
·
Jun 16

CEL-SCI - U.S. Confirmatory Registration Study for Multikine Expected to Begin Summer 2026

THOMSON REUTERS
·
Jun 16

CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy

THOMSON REUTERS
·
Jun 16

CEL-SCI partners with Saudi Amarox to pursue Multikine approval, distribution in Saudi Arabia

Reuters
·
Jun 16

Ecopetrol Temporarily Halts Brazil Tender Offer After CVM Requests Changes

TIPRANKS
·
Jun 16